Rigel Pharmaceuticals names Alison Hannah as new chief medical officer
The company disclosed the leadership change in an 8-K filed July 1, 2026, reporting an earliest event date of June 25, 2026 for the departure of the prior CMO.
Rigel Pharmaceuticals, Inc. filed a Form 8-K on July 1, 2026, with an earliest event reported date of June 25, 2026. The filing states that on July 1, 2026, the company announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company.1
In connection with her appointment, Dr. Hannah resigned from the Company's Board of Directors, effective July 1, 2026.1 She had served as a member of the Board since May 2021.1
Regarding her background, since 2000 Dr. Hannah has served as a consultant to the pharmaceutical and biotechnology industry, directing the development of investigational cancer therapies.1 Prior to her consulting work, Dr. Hannah served as Chief Medical Officer of CytomX Therapeutics and as Senior Medical Director at SUGEN, Inc.1
The filing also discloses a change involving the prior chief medical officer. Effective June 25, 2026, Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer of the Company and separated from the Company.1
The 8-K was signed by Raymond J. Furey, identified in the filing as Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary, with the document dated July 1, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.